Cowen analyst Joshua Jennings lowered the firm’s price target on Tandem Diabetes to $52 from $61 and keeps an Outperform rating on the shares. The analyst said the margin guidance is flat and slightly down year-over-year respectively which may pressure the stock near term but we still we see long-term value in the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on TNDM:
- 3 Stocks to Buy Today, 2/24/2023, According to Top Analysts
- Tandem Diabetes price target lowered to $40 from $45 at Baird
- Tandem Diabetes price target lowered to $71 from $76 at Barclays
- Tandem Diabetes sees FY23 revenue $885M-$900M, consensus $891.6M
- Tandem Diabetes reports Q4 EPS (25c), consensus (6c)